Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11307503 | 0.78 | KDM4E (0.84) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL15984890 | 0.77 | KDM4E (0.64) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL22075534 | 0.74 | KDM4E (0.58) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL18073970 | 0.72 | KDM4E (0.55) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL22075550 | 0.70 | KDM4E (0.54) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL15295521 | 0.70 | MCL1 (0.70) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL6559997 | 0.69 | GAA (0.71) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL18074001 | 0.68 | KDM4E (0.62) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL17615425 | 0.68 | ERN1 (0.66) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL11308343 | 0.68 | KDM4E (0.62) | KDM4EKMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | KDM4E 3708/4885KMT2A 1652/4885MEN1 3791/4885 |
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | NSUN3, TARBP1, TRDMT1 | KDM4E 2424/4885KMT2A 2508/4885MEN1 3917/4885 |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | NSUN3, TARBP1, TRDMT1 | KDM4E 2593/4885KMT2A 2752/4885MEN1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.